BidaskClub lowered shares of Omnicell, Inc. (NASDAQ:OMCL) from a strong-buy rating to a buy rating in a research note released on Monday, July 31st.
A number of other equities research analysts have also issued reports on the company. Piper Jaffray Companies reiterated a hold rating and issued a $40.00 target price on shares of Omnicell in a research note on Sunday, July 30th. Dougherty & Co raised their price objective on Omnicell from $45.00 to $49.00 and gave the company a buy rating in a research note on Friday, July 28th. Craig Hallum raised their price objective on Omnicell from $46.00 to $52.00 and gave the company a buy rating in a research note on Friday, July 28th. Cantor Fitzgerald reiterated a buy rating and issued a $47.00 target price on shares of Omnicell in a research report on Tuesday, July 25th. Finally, Zacks Investment Research upgraded Omnicell from a sell rating to a hold rating in a research report on Tuesday, July 4th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $49.00.
Shares of Omnicell (NASDAQ:OMCL) traded up 0.51% during mid-day trading on Monday, hitting $49.55. 244,016 shares of the stock were exchanged. Omnicell has a 52-week low of $30.35 and a 52-week high of $51.97. The stock has a 50-day moving average price of $46.29 and a 200 day moving average price of $41.70. The firm’s market cap is $1.86 billion.
Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02. The firm had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.38 earnings per share. On average, equities research analysts expect that Omnicell will post $1.31 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Omnicell, Inc. (OMCL) Downgraded to Buy at BidaskClub” was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/bidaskclub-downgrades-omnicell-inc-omcl-to-buy-updated-updated.html.
In related news, EVP Dan S. Johnston sold 16,400 shares of the business’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $48.86, for a total transaction of $801,304.00. Following the transaction, the executive vice president now directly owns 51,621 shares in the company, valued at $2,522,202.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Randall A. Lipps sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total value of $1,990,400.00. Following the completion of the sale, the chairman now owns 196,551 shares in the company, valued at $9,780,377.76. The disclosure for this sale can be found here. Insiders sold 214,932 shares of company stock valued at $10,204,151 in the last ninety days. Insiders own 3.77% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in OMCL. Renaissance Technologies LLC acquired a new position in shares of Omnicell during the fourth quarter valued at approximately $788,000. Guggenheim Capital LLC increased its position in shares of Omnicell by 75.4% in the fourth quarter. Guggenheim Capital LLC now owns 48,053 shares of the company’s stock valued at $1,628,000 after buying an additional 20,663 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Omnicell by 26.6% in the fourth quarter. AQR Capital Management LLC now owns 24,935 shares of the company’s stock valued at $845,000 after buying an additional 5,236 shares during the last quarter. Norges Bank acquired a new position in shares of Omnicell during the fourth quarter valued at approximately $10,913,000. Finally, UBS Asset Management Americas Inc. increased its position in shares of Omnicell by 9.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 188,158 shares of the company’s stock valued at $6,378,000 after buying an additional 15,779 shares during the last quarter. 96.35% of the stock is currently owned by institutional investors and hedge funds.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.